Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jul;80(9):1427–1434. doi: 10.1038/sj.bjc.6690539

p27KIP1 is abnormally expressed in Diffuse Large B-Cell Lymphomas and is associated with an adverse clinical outcome

Al Sáez 1, E Sánchez 1, M Sánchez-Beato 1, M A Cruz 1, I Chacón 1, E Muñoz 1, F I Camacho 1, J C Martínez-Montero 1, M Mollejo 1, J F Garcia 1, M A Piris 1
PMCID: PMC2363083  PMID: 10424746

Abstract

Cell cycle progression is regulated by the combined action of cyclins, cyclin-dependent kinases (CDKs), and CDK-inhibitors (CDKi), which are negative cell cycle regulators. p27KIP1 is a CDKi key in cell cycle regulation, whose degradation is required for G1/S transition. In spite of the absence of p27KIP1 expression in proliferating lymphocytes, some aggressive B-cell lymphomas have been reported to show an anomalous p27KIP1 staining. We analysed p27KIP1 expression in a series of Diffuse Large B-cell Lymphoma (DLBCL), correlating it with the proliferative index and clinical outcome, to characterize the implications of this anomalous staining in lymphomagenesis in greater depth. For the above mentioned purposes, an immunohistochemical technique in paraffin-embedded tissues was employed, using commercially available antibodies, in a series of 133 patients with known clinical outcomes. Statistical analysis was performed in order to ascertain which clinical and molecular variables may influence outcome, in terms of disease-free survival (DFS) and overall survival (OS). The relationships between p27KIP1 and MIB-1 (Ki-67) were also tested. An abnormally high expression of p27KIP1 was found in lymphomas of this type. The overall correlation between p27KIP1 and MIB-1 showed there to be no significant relationship between these two parameters, this differing from observations in reactive lymphoid and other tissues. Analysis of the clinical relevance of these findings showed that a high level of p27KIP1 expression in this type of tumour is an adverse prognostic marker, in both univariate and multivariate analysis. These results show that there is abnormal p27KIP1 expression in DLBCL, with adverse clinical significance, suggesting that this anomalous p27KIP1 protein may be rendered non-functional through interaction with other cell cycle regulator proteins. © 1999 Cancer Research Campaign

Keywords: p27KIP1, MIB1, CDK inhibitors, diffuse large B-cell lymphoma, survival analysis

Full Text

The Full Text of this article is available as a PDF (399.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blain S. W., Montalvo E., Massagué J. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J Biol Chem. 1997 Oct 10;272(41):25863–25872. doi: 10.1074/jbc.272.41.25863. [DOI] [PubMed] [Google Scholar]
  2. Catzavelos C., Bhattacharya N., Ung Y. C., Wilson J. A., Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997 Feb;3(2):227–230. doi: 10.1038/nm0297-227. [DOI] [PubMed] [Google Scholar]
  3. Chan F. K., Zhang J., Cheng L., Shapiro D. N., Winoto A. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol. 1995 May;15(5):2682–2688. doi: 10.1128/mcb.15.5.2682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cheng M., Sexl V., Sherr C. J., Roussel M. F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1091–1096. doi: 10.1073/pnas.95.3.1091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coats S., Flanagan W. M., Nourse J., Roberts J. M. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science. 1996 May 10;272(5263):877–880. doi: 10.1126/science.272.5263.877. [DOI] [PubMed] [Google Scholar]
  6. Erlanson M., Portin C., Linderholm B., Lindh J., Roos G., Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood. 1998 Aug 1;92(3):770–777. [PubMed] [Google Scholar]
  7. Esposito V., Baldi A., De Luca A., Groger A. M., Loda M., Giordano G. G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997 Aug 15;57(16):3381–3385. [PubMed] [Google Scholar]
  8. Fang F., Orend G., Watanabe N., Hunter T., Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science. 1996 Jan 26;271(5248):499–502. doi: 10.1126/science.271.5248.499. [DOI] [PubMed] [Google Scholar]
  9. Fero M. L., Rivkin M., Tasch M., Porter P., Carow C. E., Firpo E., Polyak K., Tsai L. H., Broudy V., Perlmutter R. M. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell. 1996 May 31;85(5):733–744. doi: 10.1016/s0092-8674(00)81239-8. [DOI] [PubMed] [Google Scholar]
  10. Fredersdorf S., Burns J., Milne A. M., Packham G., Fallis L., Gillett C. E., Royds J. A., Peston D., Hall P. A., Hanby A. M. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6380–6385. doi: 10.1073/pnas.94.12.6380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gascoyne R. D., Adomat S. A., Krajewski S., Krajewska M., Horsman D. E., Tolcher A. W., O'Reilly S. E., Hoskins P., Coldman A. J., Reed J. C. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997 Jul 1;90(1):244–251. [PubMed] [Google Scholar]
  12. Grogan T. M., Lippman S. M., Spier C. M., Slymen D. J., Rybski J. A., Rangel C. S., Richter L. C., Miller T. P. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood. 1988 Apr;71(4):1157–1160. [PubMed] [Google Scholar]
  13. Guan K. L., Jenkins C. W., Li Y., Nichols M. A., Wu X., O'Keefe C. L., Matera A. G., Xiong Y. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 1994 Dec 15;8(24):2939–2952. doi: 10.1101/gad.8.24.2939. [DOI] [PubMed] [Google Scholar]
  14. Hannon G. J., Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994 Sep 15;371(6494):257–261. doi: 10.1038/371257a0. [DOI] [PubMed] [Google Scholar]
  15. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993 Nov 19;75(4):805–816. doi: 10.1016/0092-8674(93)90499-g. [DOI] [PubMed] [Google Scholar]
  16. Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K., Cleary M. L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K. C. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994 Sep 1;84(5):1361–1392. [PubMed] [Google Scholar]
  17. Hengst L., Reed S. I. Translational control of p27Kip1 accumulation during the cell cycle. Science. 1996 Mar 29;271(5257):1861–1864. doi: 10.1126/science.271.5257.1861. [DOI] [PubMed] [Google Scholar]
  18. Hermine O., Haioun C., Lepage E., d'Agay M. F., Briere J., Lavignac C., Fillet G., Salles G., Marolleau J. P., Diebold J. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 1996 Jan 1;87(1):265–272. [PubMed] [Google Scholar]
  19. Hill M. E., MacLennan K. A., Cunningham D. C., Vaughan Hudson B., Burke M., Clarke P., Di Stefano F., Anderson L., Vaughan Hudson G., Mason D. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood. 1996 Aug 1;88(3):1046–1051. [PubMed] [Google Scholar]
  20. Kato J. Y., Matsuoka M., Polyak K., Massagué J., Sherr C. J. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell. 1994 Nov 4;79(3):487–496. doi: 10.1016/0092-8674(94)90257-7. [DOI] [PubMed] [Google Scholar]
  21. Kawamata N., Morosetti R., Miller C. W., Park D., Spirin K. S., Nakamaki T., Takeuchi S., Hatta Y., Simpson J., Wilcyznski S. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 1995 Jun 1;55(11):2266–2269. [PubMed] [Google Scholar]
  22. Kiyokawa H., Kineman R. D., Manova-Todorova K. O., Soares V. C., Hoffman E. S., Ono M., Khanam D., Hayday A. C., Frohman L. A., Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell. 1996 May 31;85(5):721–732. doi: 10.1016/s0092-8674(00)81238-6. [DOI] [PubMed] [Google Scholar]
  23. Kramer M. H., Hermans J., Parker J., Krol A. D., Kluin-Nelemans J. C., Haak H. L., van Groningen K., van Krieken J. H., de Jong D., Kluin P. M. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol. 1996 Jul;14(7):2131–2138. doi: 10.1200/JCO.1996.14.7.2131. [DOI] [PubMed] [Google Scholar]
  24. Lee M. H., Reynisdóttir I., Massagué J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 1995 Mar 15;9(6):639–649. doi: 10.1101/gad.9.6.639. [DOI] [PubMed] [Google Scholar]
  25. Loda M., Cukor B., Tam S. W., Lavin P., Fiorentino M., Draetta G. F., Jessup J. M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997 Feb;3(2):231–234. doi: 10.1038/nm0297-231. [DOI] [PubMed] [Google Scholar]
  26. Mantel C., Luo Z., Canfield J., Braun S., Deng C., Broxmeyer H. E. Involvement of p21cip-1 and p27kip-1 in the molecular mechanisms of steel factor-induced proliferative synergy in vitro and of p21cip-1 in the maintenance of stem/progenitor cells in vivo. Blood. 1996 Nov 15;88(10):3710–3719. [PubMed] [Google Scholar]
  27. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  28. Martin A. R., Weisenburger D. D., Chan W. C., Ruby E. I., Anderson J. R., Vose J. M., Bierman P. J., Bast M. A., Daley D. T., Armitage J. O. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood. 1995 Jun 15;85(12):3671–3678. [PubMed] [Google Scholar]
  29. Matsuoka S., Edwards M. C., Bai C., Parker S., Zhang P., Baldini A., Harper J. W., Elledge S. J. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995 Mar 15;9(6):650–662. doi: 10.1101/gad.9.6.650. [DOI] [PubMed] [Google Scholar]
  30. Miller T. P., Grogan T. M., Dahlberg S., Spier C. M., Braziel R. M., Banks P. M., Foucar K., Kjeldsberg C. R., Levy N., Nathwani B. N. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994 Mar 15;83(6):1460–1466. [PubMed] [Google Scholar]
  31. Morosétti R., Kawamata N., Gombart A. F., Miller C. W., Hatta Y., Hirama T., Said J. W., Tomonaga M., Koeffler H. P. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood. 1995 Sep 1;86(5):1924–1930. [PubMed] [Google Scholar]
  32. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D. Y., Nakayama K. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996 May 31;85(5):707–720. doi: 10.1016/s0092-8674(00)81237-4. [DOI] [PubMed] [Google Scholar]
  33. Nourse J., Firpo E., Flanagan W. M., Coats S., Polyak K., Lee M. H., Massague J., Crabtree G. R., Roberts J. M. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994 Dec 8;372(6506):570–573. doi: 10.1038/372570a0. [DOI] [PubMed] [Google Scholar]
  34. Piris M. A., Pezzella F., Martinez-Montero J. C., Orradre J. L., Villuendas R., Sanchez-Beato M., Cuena R., Cruz M. A., Martinez B., Pezella F [corrected to Pezzella F. ]. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer. 1994 Feb;69(2):337–341. doi: 10.1038/bjc.1994.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Polyak K., Lee M. H., Erdjument-Bromage H., Koff A., Roberts J. M., Tempst P., Massagué J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994 Jul 15;78(1):59–66. doi: 10.1016/0092-8674(94)90572-x. [DOI] [PubMed] [Google Scholar]
  36. Porter P. L., Malone K. E., Heagerty P. J., Alexander G. M., Gatti L. A., Firpo E. J., Daling J. R., Roberts J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997 Feb;3(2):222–225. doi: 10.1038/nm0297-222. [DOI] [PubMed] [Google Scholar]
  37. Quintanilla-Martinez L., Thieblemont C., Fend F., Kumar S., Pinyol M., Campo E., Jaffe E. S., Raffeld M. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol. 1998 Jul;153(1):175–182. doi: 10.1016/S0002-9440(10)65558-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Reynisdóttir I., Massagué J. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 1997 Feb 15;11(4):492–503. doi: 10.1101/gad.11.4.492. [DOI] [PubMed] [Google Scholar]
  39. Sanchez E., Chacon I., Plaza M. M., Muñoz E., Cruz M. A., Martinez B., Lopez L., Martinez-Montero J. C., Orradre J. L., Saez A. I. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol. 1998 May;16(5):1931–1939. doi: 10.1200/JCO.1998.16.5.1931. [DOI] [PubMed] [Google Scholar]
  40. Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704–707. doi: 10.1038/366704a0. [DOI] [PubMed] [Google Scholar]
  41. Sgambato A., Zhang Y. J., Arber N., Hibshoosh H., Doki Y., Ciaparrone M., Santella R. M., Cittadini A., Weinstein I. B. Deregulated expression of p27(Kip1) in human breast cancers. Clin Cancer Res. 1997 Oct;3(10):1879–1887. [PubMed] [Google Scholar]
  42. Shiohara M., el-Deiry W. S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D. L., Vogelstein B., Koeffler H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood. 1994 Dec 1;84(11):3781–3784. [PubMed] [Google Scholar]
  43. Slymen D. J., Miller T. P., Lippman S. M., Spier C. M., Kerrigan D. P., Rybski J. A., Rangel C. S., Richter L. C., Grogan T. M. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol. 1990 Jun;8(6):986–993. doi: 10.1200/JCO.1990.8.6.986. [DOI] [PubMed] [Google Scholar]
  44. Soos T. J., Kiyokawa H., Yan J. S., Rubin M. S., Giordano A., DeBlasio A., Bottega S., Wong B., Mendelsohn J., Koff A. Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ. 1996 Feb;7(2):135–146. [PubMed] [Google Scholar]
  45. St Croix B., Flørenes V. A., Rak J. W., Flanagan M., Bhattacharya N., Slingerland J. M., Kerbel R. S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med. 1996 Nov;2(11):1204–1210. doi: 10.1038/nm1196-1204. [DOI] [PubMed] [Google Scholar]
  46. Sánchez-Beato M., Sáez A. I., Martínez-Montero J. C., Sol Mateo M., Sánchez-Verde L., Villuendas R., Troncone G., Piris M. A. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol. 1997 Jul;151(1):151–160. [PMC free article] [PubMed] [Google Scholar]
  47. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994 Jul 15;78(1):67–74. doi: 10.1016/0092-8674(94)90573-8. [DOI] [PubMed] [Google Scholar]
  48. Vrhovac R., Delmer A., Tang R., Marie J. P., Zittoun R., Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood. 1998 Jun 15;91(12):4694–4700. [PubMed] [Google Scholar]
  49. Wang X., Gorospe M., Huang Y., Holbrook N. J. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene. 1997 Dec 11;15(24):2991–2997. doi: 10.1038/sj.onc.1201450. [DOI] [PubMed] [Google Scholar]
  50. Watanabe H., Fukuchi K., Takagi Y., Tomoyasu S., Tsuruoka N., Gomi K. Molecular analysis of the Cip1/Waf1 (p21) gene in diverse types of human tumors. Biochim Biophys Acta. 1995 Sep 19;1263(3):275–280. doi: 10.1016/0167-4781(95)00110-3. [DOI] [PubMed] [Google Scholar]
  51. Yamanaka N., Harabuchi Y., Kataura A. The prognostic value of Ki-67 antigen in non-Hodgkin lymphoma of Waldeyer ring and the nasal cavity. Cancer. 1992 Nov 1;70(9):2342–2349. doi: 10.1002/1097-0142(19921101)70:9<2342::aid-cncr2820700922>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  52. Yatabe Y., Masuda A., Koshikawa T., Nakamura S., Kuroishi T., Osada H., Takahashi T., Mitsudomi T., Takahashi T. p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res. 1998 Mar 1;58(5):1042–1047. [PubMed] [Google Scholar]
  53. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES